Our pipeline
We have an exciting and balanced pipeline underpinned by great science.
Home / Our therapy areas / Our pipeline
Latest quarterly updates
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
178
projects in our pipeline
17
new molecular entities in our late-stage pipeline
3
new molecular entities under review
Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).
Oncology (as of 8 February 2024)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Cardiovascular, Renal and Metabolism (as of 8 February 2024)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Respiratory & Immunology (as of 8 February 2024)
Phase I
Phase I
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Rare Disease (as of 8 February 2024)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Vaccine & Immune therapies (as of 8 February 2024)
Phase I
Phase I
Phase II
Phase II
Phase III
LCM Projects
LCM Projects
Other (as of 8 February 2024)
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Removed since last quarter
Veeva ID: Z4-57208
Date of preparation: August 2023